IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
2026-07-19 00:16
•Cory Renauer •The Motley Fool
••• ••••••• Axe Capital view
IHE vs IXJ: Picking the Right Healthcare ETF for South African Investors
Comparing concentrated U.S. pharma ETF IHE against diversified global healthcare ETF IXJ through a South African lens.
IHE’s recent hefty returns are tempting, driven by weight-loss blockbuster drugs from a couple of companies. But with nearly half the fund tied up in Johnson & Johnson and Eli Lilly, the risk is clear—any hiccup in these stocks could hit hard. IXJ, on the other hand, spreads that risk across multiple countries and healthcare sectors. For JSE investors, this matters because healthcare is typically a defensive asset class worth having, but concentration risk could make IHE volatile against rand fluctuations. Given the rand’s sensitivity to global risk and dollar strength, IXJ’s global diversification helps smooth returns in rand terms. If you’re after growth and can stomach swings, IHE might suit. For steadier rand-hedged exposure, lean toward IXJ. Keep an eye on currency moves too, as a weaker rand boosts your dollar assets but may pressure costs for companies with imported goods. this is just my opinion and not financial advice
I’d recommend watching IXJ for diversified exposure and better risk balance in the current environment while keeping IHE on the radar for tactical plays if you’re comfortable with higher concentration and volatility.
- IHE
- IXJ
- USD/ZAR
- Concentration risk in IHE’s top holdings
- Rand volatility impacting offshore healthcare returns
6/10
The article compares two healthcare ETFs: IHE (U.S. Pharmaceuticals) and IXJ (Global Healthcare). IHE offers concentrated exposure to 56 U.S. pharmaceutical companies with higher recent returns (50.30% 1-yr), but carries significant concentration risk with its top two holdings (J&J and Eli Lilly) comprising 43% of the portfolio. IXJ provides broader diversification across 110 international healthcare companies including medical devices and services, with lower concentration risk but more modest recent returns (18.20% 1-yr). The article suggests IXJ is better for diversification-focused investors, while IHE's outperformance is largely driven by GLP-1 weight-loss drug success.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Cory Renauer
Categories: Equities, Earnings, Healthcare
Tickers: IHE, IXJ, JNJ, LLY, BMY, CELGR, ABBV
Sentiment: Positive - Strong recent performance (50.30% 1-yr return) but criticized for high concentration risk with top two holdings representing 43% of portfolio. Outperformance is attributed to a single trend (GLP-1 drugs), making it vulnerable to sector-specific downturns. Recommended for diversification-focused investors due to broader exposure across 110 international holdings, multiple healthcare subsectors (pharmaceuticals, medical devices, services, insurance), and lower concentration risk. Better positioned to weather sector-specific challenges.
Keywords: healthcare ETF, pharmaceutical stocks, portfolio diversification, concentration risk, GLP-1 drugs, international healthcare
Insights:
- IHE: Neutral: Strong recent performance (50.30% 1-yr return) but criticized for high concentration risk with top two holdings representing 43% of portfolio. Outperformance is attributed to a single trend (GLP-1 drugs), making it vulnerable to sector-specific downturns.
- IXJ: Positive: Recommended for diversification-focused investors due to broader exposure across 110 international holdings, multiple healthcare subsectors (pharmaceuticals, medical devices, services, insurance), and lower concentration risk. Better positioned to weather sector-specific challenges.
- JNJ: Neutral: Major holding in both ETFs (21.81% in IHE, 6.89% in IXJ). Noted as having diversified revenue streams beyond pharmaceuticals, with over one-third of income from medical devices.